References
- Ludwig H, Novis Durie S, Meckl A, et al. Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment. Oncologist. 2020;25(9):e1406-13–e1413.
- Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266–2275.
- Celgene. ABECMA (idecabtagene vicleucel) [prescribing information]. Summit, NJ: Celgene Corporation, a Bristol-Myers Squibb Company; 2021.
- Celgene. Abecma (idecabtagene vicleucel) [summary of product characteristics]. Utrecht, Netherlands: Celgene Europe B.V; 2021.
- Bristol Myers Squibb. Health Canada approves ABECMATM (idecabtagene vicleucel), the first and only anti-BCMA CAR T cell therapy for relapsed and refractory multiple myeloma. 2021. Available from: https://www.bms.com/ca/en/media/press-release-listing/2021-05-31-press-release.html#:∼:text=Health%20Canada%20Approves%20ABECMATM,Relapsed%20and%20Refractory%20Multiple%20Myeloma&text=%E2%80%9CToday’s%20approval%20is%20an%20important,i. n%20Canada%2C%E2%80%9D%20says%20Dr.Pu.
- Bristol Myers Squibb. Bristol Myers Squibb receives approval for Abecma (idecabtagene vicleucel), the first CAR T therapy approved for the treatment of multiple myeloma in Japan; 2022. Available from: https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Receives-Approval-for-Abecma-idecabtagene-vicleucel-the-First-CAR-T-Therapy-Approved-for-the-Treatment-of-Multiple-Myeloma-in-Japan/default.aspx.
- Seefat MR, Cucchi DGJ, Dirven S, et al. A systematic review of cost-effectiveness analyses of novel agents in the treatment of multiple myeloma. Cancers. 2021;13(22):5606.
- National Institute for Health Care and Excellence [INTERNET]. Panobinostat for treating multiple myeloma after at least 2 previous treatments [TA 380]; 2016. Available from: https://www.nice.org.uk/guidance/ta380.
- National Institute for Health Care and Excellence [INTERNET]. Daratumumab monotherapy for treating relapsed and refractory multiple myeloma: technology appraisal guidance [TA510]; 2018. Available from: https://www.nice.org.uk/guidance/ta510.
- National Institute for Health Care and Excellence [INTERNET]. Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib [TA 427]; 2016. Available from: https://www.nice.org.uk/guidance/ta427.
- National Institute for Health Care and Excellence [INTERNET]. Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma [TA505]; 2018. Availalble from: https://www.nice.org.uk/guidance/ta505/.
- Beinfeld M, Lee S, McQueen B, et al. Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pretreated relapsed and refractory multiple myeloma. J Manag Care Spec Pharm. 2021;27(9):1315–1320.
- Anderson LD, Shah N, Jagannath S, et al. OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa. Clin Lymphoma Myeloma Leuk. 2021;21(Suppl 2):S17–S18.
- Jagannath S, Lin Y, Goldschmidt H, et al. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. Blood Cancer J. 2021;11(6):116.
- Munshi NC, Anderson LD, Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–716.
- Belcher SM, Watkins Bruner D, Hofmeister CC, et al. Characterizing pain experiences: african American patients with multiple myeloma taking around-the-clock opioids. Clin J Oncol Nurs. 2020;24(5):538–546.
- Benyounes A, Ma N, Kocoglu M, et al. Racial disparities in multiple myeloma patients with durable stringent complete response. Clin Lymphoma Myeloma Leuk. 2019;19(10):e287.
- Blue BJ, Luo S, Sanfilippo KM, et al. Race-based differences in routine cytogenetic profiles of patients with multiple myeloma. Br J Haematol. 2017;176(2):322–324.
- Boyd KD, Ross FM, Chiecchio L, et al. Gender disparities in the tumor genetics and clinical outcome of multiple myeloma. Cancer Epidemiol Biomarkers Prev. 2011;20(8):1703–1707.
- Bunce CM, Drayson MT. Dissecting racial disparities in multiple myeloma-clues from differential immunoglobulin levels. Blood Cancer J. 2020;10(4):44.
- Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381(8):727–738.
- Shah JJ, Stadtmauer EA, Abonour R, et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015;126(20):2284–2290.
- Bringhen S, Petrucci MT, Larocca A, et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood. 2014;124(1):63–69.
- Canadian Agency for Drugs and Technologies in Health [INTERNET]. CADTH reimbursement review: idecabtagene vicleucel (Abecma): Canadian Journal of Health Technologies; 2022. Available from: https://doi.org/https://www.cadth.ca/sites/default/files/DRR/2022/PG0240-Abecma.pdf
- Prica A, Hay AE, Crump M, et al. Evaluating the indirect costs of care associated with salvage chemotherapy for relapsed and refractory aggressive-histology lymphoma: a subset analysis of the Canadian cancer trials group (CCTG) LY.12 clinical trial. Curr Oncol. 2021;28(2):1256–1261.
- Jackson G, Galinsky J, Alderson DC, et al. Productivity losses in patients with newly diagnosed multiple myeloma following stem cell transplantation and the impact of maintenance therapy. Eur J Haematol. 2019;103(4):393–401.
- Statistics Canada. Table 14-10-0060-01 Retirement age by class of worker, annual. [last updated 2023 Jan 6]. DOI:10.25318/1410006001-eng
- Weisel K, Paner A, Engelhardt M, et al. Quality-of-life outcomes in patients with relapsed/refractory multiple myeloma treated with elotuzumab plus pomalidomide and dexamethasone: results from the phase 2 randomized ELOQUENT-3 study. Blood. 2018;132(Supplement 1):2288–2288.
- Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large b-cell lymphoma. N Engl J Med. 2019;380(1):45–56.
- European Medicines Agency [INTERNET]. CARVYKTI (Ciltacabtagene Autoleucel) Summary of product characteristics; 2022. Avaialble from: https://www.ema.europa.eu/en/documents/product-information/carvykti-epar-product-information_en.pdf.
- Delforge M, Shah N, Miguel JSF, et al. Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma. Blood Adv. 2022;6(4):1309–1318.
- Institute for Clinical and Economic Review [INTERNET]. Anti b-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pre-treated relapsed and refractory multiple myeloma. 2021. Available from: https://icer.org/wp-content/uploads/2020/10/ICER_Multiple-Myeloma_Final-Report_Update_070921.pdf.
- Canadian Agency for Drugs and Technologies in Health [INTERNET]. Pan-canadian oncology drug review registered clinician feedback on a pCODR expert review committee initial recommendation pomalidomide (Pomalyst) for multiple myeloma; 2014. Available from: https://www.cadth.ca/sites/default/files/pcodr/pcodr-pomalyst-mm-fn-egr.pdf.
- Scottish Medicines Consortium [INTERNET]. Daratumumab (Darzalex). Advice. SMC1205/17; 2017. Available from: https://www.scottishmedicines.org.uk/medicines-advice/daratumumab-darzalex-resubmission-120517/.
- Pelligra CG, Parikh K, Guo S, et al. Cost-effectiveness of pomalidomide, carfilzomib, and daratumumab for the treatment of patients with heavily pretreated relapsed-refractory multiple myeloma in the United States. Clin Ther. 2017;39(10):1986–2005.e5.
- Zhang TT, Wang S, Wan N, et al. Cost-effectiveness of daratumumab-based triplet therapies in patients with relapsed or refractory multiple myeloma. Clin Ther. 2018;40(7):1122–1139.
- Roth JA, Sullivan SD, Lin VW, et al. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. J Med Econ. 2018;21(12):1238–1245.
- Qi CZ, Bollu V, Yang H, et al. Cost-effectiveness analysis of tisagenlecleucel for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma in the United States. Clin Ther. 2021;43(8):1300–1319.e8.
- Ontario Case Costing Initiative. 2019. https://data.ontario.ca/dataset/ontario-case-costing-initiative-occi.
- Canadian Agency for Drugs and Technologies in Health. Pan-Canadian Oncology Drug Review Registered Clinician Feedback on a pCODR Expert Review Committee Initial Recommendation Daratumumab (Darzalex) for Multiple Myeloma. 2017. https://www.cadth.ca/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_2ndln_fn_egr.pdf.
- Canadian Agency for Drugs and Technologies in Health. Pan-Canadian Oncology Drug Review Final Economic Guidance Report Bortezomib (Velcade) for Multiple Myeloma. 2013. https://www.cadth.ca/sites/default/files/pcodr/pcodr-velcademm-fn-egr.pdf.
- Canadian Agency for Drugs and Technologies in Health. Pan-Canadian Oncology Drug Review Final Economic Guidance Report Carfilzomib (Kyprolis) for Multiple Myeloma. 2017. https://www.cadth.ca/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_rel_fn_egr.pdf.
- Ontario Drug Benefit Formulary. https://www.formulary.health.gov.on.ca/formulary/.
- Aide au Codage. https://www.aideaucodage.fr/ccam.
- Canadian Institute for Health Information. Cost of a Standard Hospital Stay. https://yourhealthsystem.cihi.ca/hsp/inbrief.#!/indicators/015/cost-of-a-standard-hospital-stay/;mapC1;mapLevel2;/.
- Ontario Health Insurance Plan. Schedule of Benefits for Laboratory Services, 2020. https://health.gov.on.ca/en/pro/programs/ohip/sob/lab/lab_mn2020.pdf.
- Autorité de Santé H. Rapport d‘activité. 2015. [Internet]. Disponible sur: https://www.has-sante.fr/upload/docs/application/pdf/2016-07/rapport_activite_2015.pdf.
- Gonzalez-McQuire S, Yong K, Leleu H, et al. Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy. J Med Econ. 2018;21(5):450–467.
- de Oliveira C, Pataky R, Bremner KE, et al. Phase-specific and lifetime costs of cancer care in Ontario, Canada. BMC Cancer. 2016;16(1):809.